/
ENGN
$1.78+$0.03 (+1.71%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$117.2M
67M shares
52-week range
$1.40 – $12.25
4% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
2.73%
Moderate
Price (6 mo)
Loading chart…
Change$-18.22
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — |
| R&D | $10.6M | $12.5M | $15.5M | $16.5M | $38.3M | $94.5M |
| Operating income | −$13.9M | −$15.9M | −$19.4M | −$26.1M | −$62.3M | −$123.2M |
| EBITDA | −$12.9M | −$18.1M | −$22.8M | −$94.8M | −$52.0M | −$113.8M |
| Net income | −$15.1M | −$23.4M | −$24.5M | −$99.9M | −$55.1M | −$117.3M |
| Net margin | — | — | — | — | — | — |
| EPS (diluted) | -0.95 | -0.01 | 0.00 | -4.24 | -1.46 | -2.29 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $5M | $-1.76 | $-2.03–$-1.53 | 6 |
| 2027 | $6M | $-1.49 | $-2.11–$-0.92 | 6 |
| 2028 | $38M | $-0.99 | $-1.26–$-0.73 | 5 |
| 2029 | $98M | $-0.54 | $-0.68–$-0.39 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.28
Price
$1.78
Implied downside
-84%
Peer comparison
enGene Therapeutics Inc. Common Stock
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
www.engene.com- Employees
- 82
- IPO / List date
- Nov 1, 2023
- HQ
- SAINT-LAURENT
Held by traders on TradeandTell
No one on the platform currently holds ENGN.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ENGN as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ENGN yet.
